Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) – Pipeline Review, H1 2018’, provides in depth analysis on Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System, Immunology, Respiratory, Gastrointestinal, Ophthalmology, Cardiovascular, Dermatology, Genito Urinary System And Sex Hormones, Metabolic Disorders, Musculoskeletal Disorders, Non Malignant Disorders and Oncology under development targeting Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1)

– The report reviews Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

– The report assesses Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AbbVie Inc

Angion Biomedica Corp

Astex Pharmaceuticals Inc

BioAxone BioSciences Inc

HitGen LTD

Kadmon Corp LLC

Pfizer Inc

Redx Pharma Plc

Vertex Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC

2.7.11.1) Overview

Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC

2.7.11.1) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC

2.7.11.1) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC

2.7.11.1) Companies Involved in Therapeutics Development

AbbVie Inc

Angion Biomedica Corp

Astex Pharmaceuticals Inc

BioAxone BioSciences Inc

HitGen LTD

Kadmon Corp LLC

Pfizer Inc

Redx Pharma Plc

Vertex Pharmaceuticals Inc

Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC

2.7.11.1) Drug Profiles

AMA-0825 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AN-3485 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANG-4201 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-13148 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BA-1049 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BA-1076 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KD-025 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KL-00148 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KL-00974 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KL-01045 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit ROCK-2 for Cardiovascular, Ophthalmology, Metabolic Disorders and Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit ROCK2 for Fibrotic Diseases Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ROCK1 and ROCK 2 for Pain Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Selectively Inhibit ROCK2 for Autoimmune Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRX-101 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VX-210 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC

2.7.11.1) Dormant Products

Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC

2.7.11.1) Discontinued Products

Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC

2.7.11.1) Product Development Milestones

Featured News & Press Releases

Feb 12, 2018: Kadmon Announces Positive Topline Results from Phase 2 Study of KD025 in Idiopathic Pulmonary Fibrosis

Feb 12, 2018: Kadmon to Host Webcast and Conference Call to Discuss Topline Results of KD025 in IPF

Dec 10, 2017: Kadmon Presents Updated Positive Phase 2 Data on KD025 in cGVHD at ASH Annual Meeting

Nov 01, 2017: Kadmon to Present New Data from Ongoing Phase 2 Study of KD025 in cGVHD at ASH Annual Meeting

Oct 06, 2017: FDA Grants Orphan Drug Designation to Kadmon’s KD025 for the Treatment of cGVHD

Aug 11, 2017: Kadmon to Present Preclinical Data on ROCK Inhibition in Pulmonary Fibrosis at IPF Summit 2017

Aug 02, 2017: BioAxone BioSciences Receives Notice of Award for NIH/SBIR Funding of IND-Enabling Studies to Continue Development of BA-1049 to Treat Cerebral Cavernous Malformations

Jul 25, 2017: Kadmon Announces Supplemental Interim Phase 2 Data of KD025 in Chronic Graft-Versus-Host Disease

Jul 11, 2017: Kadmon Announces Interim Phase 2 Data of KD025 in Chronic Graft-Versus-Host Disease

Jun 23, 2017: Kadmon to Present Interim Data on KD025 in Chronic Graft-Versus-Host Disease at R&D Day

May 11, 2017: Kadmon to Present Clinical and Preclinical Data Highlighting the Role of ROCK2 Signaling in Immune System Function at AAI Annual Meeting

May 11, 2017: BioAxone BioSciences Announces New Hires to Support Investigational New Drug Filing

May 02, 2017: BioAxone BioSciences Continues Plans for Growth with Manufacturing Contract

Apr 12, 2017: Kadmon Announces Publication of Clinical Data Showing KD025 Improved Clinical Scores in Psoriasis Patients

Mar 28, 2017: Kadmon Presents Preclinical Data Supporting the Therapeutic Potential of ROCK Inhibition in Pulmonary Fibrosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by AbbVie Inc, H1 2018

Pipeline by Angion Biomedica Corp, H1 2018

Pipeline by Astex Pharmaceuticals Inc, H1 2018

Pipeline by BioAxone BioSciences Inc, H1 2018

Pipeline by HitGen LTD, H1 2018

Pipeline by Kadmon Corp LLC, H1 2018

Pipeline by Pfizer Inc, H1 2018

Pipeline by Redx Pharma Plc, H1 2018

Pipeline by Vertex Pharmaceuticals Inc, H1 2018

Dormant Projects, H1 2018

Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared